Sun Pharma deal
India’s largest pharmaceutical company Sun Pharma is moving towards a historic acquisition. The company has made a binding offer of about $13 billion to buy American pharma firm Organon & Company. If this deal is completed, it will not only be Sun Pharma’s biggest purchase till date, but will also prove to be a big step towards transforming the Indian generic pharmaceutical company into a global branded and innovative pharma player. Big players like EQT and Grünthal are also involved in this race, which has made the competition quite interesting.
Dilip Shanghvi-led Sun Pharma has made an all-cash offer of $13 billion to buy American company Organon. This acquisition is considered to be the biggest bet for the company so far. Through this deal, Sun Pharma wants to expand its business beyond generic medicines and strengthen it in the innovative and specialty pharma segments. According to sources, JP Morgan, MUFG and Citi Bank are financing about $ 12 billion for this deal. Under the plan, NYSE-listed Organon will be merged with Sun Pharma upon completion of the deal, although Organon shareholders will not receive Sun Pharma shares.
What does Organon Company do?
Organon is a company focused on women’s health. Its portfolio includes medicines related to breast cancer, contraception, osteoporosis and menopause. Apart from this, the company is also expanding rapidly in biosimilar medicines, which can become a big growth driver in the future. However, there is also a big risk in this deal. Organon has a debt of about $8.64 billion by the end of 2025, which the acquiring company will have to refinance. Sun Pharma is preparing to use its net cash of about $3.2 billion along with the financing plan to handle this debt.
Market experts believe that this deal can be positive for Organon. At the same time, it may prove risky for Sun Pharma. Due to this, the company’s focus may shift from domestic specialty business and its debt burden may also increase. Meanwhile, Organon’s shares have seen a rise of about 52% in the last one month, which has come due to the discussion about this possible deal. At the same time, giants like EQT and Grünthal are also involved in this race, due to which the competition has become more intense. If this deal is successful, Sun Pharma will not only grow in size but will also be able to further strengthen its hold in the global pharma industry.
Also read- Microsoft and Meta’s plans threaten jobs, 23 thousand people may lose their jobs!
